<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Disease‐modifying treatments for primary autoimmune haemolytic anaemia - Liu, A-yP - 2021 | Cochrane Library</title> <meta content="Disease‐modifying treatments for primary autoimmune haemolytic anaemia - Liu, A-yP - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012493.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Disease‐modifying treatments for primary autoimmune haemolytic anaemia - Liu, A-yP - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012493.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012493.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Disease‐modifying treatments for primary autoimmune haemolytic anaemia" name="citation_title"/> <meta content="Anthony Pak-yin Liu" name="citation_author"/> <meta content="The University of Hong Kong, Queen Mary Hospital" name="citation_author_institution"/> <meta content="apyliu@hku.hk" name="citation_author_email"/> <meta content="Daniel KL Cheuk" name="citation_author"/> <meta content="The University of Hong Kong, Queen Mary Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012493.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/03/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012493.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012493.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012493.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia, Hemolytic, Autoimmune [*drug therapy]; Bias; Confidence Intervals; Drug Therapy, Combination [methods]; Erythrocyte Transfusion; Glucocorticoids [administration &amp; dosage, *therapeutic use]; Immunologic Factors [administration &amp; dosage, *therapeutic use]; Prednisolone [administration &amp; dosage, *therapeutic use]; Randomized Controlled Trials as Topic; Rituximab [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012493.pub2&amp;doi=10.1002/14651858.CD012493.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="IregKd2C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012493\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012493\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012493.pub2",title:"Disease\\u2010modifying treatments for primary autoimmune haemolytic anaemia",firstPublishedDate:"Mar 31, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012493.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012493.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012493.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012493.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012493.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012493.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012493.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012493.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012493.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012493.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5443 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012493.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-sec-0059"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-sec-0053"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/appendices#CD012493-sec-0064"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/table_n/CD012493StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/table_n/CD012493StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Disease‐modifying treatments for primary autoimmune haemolytic anaemia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/information#CD012493-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Anthony Pak-yin Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012493.pub2/information#CD012493-cr-0005">Daniel KL Cheuk</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/information/en#CD012493-sec-0071">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 March 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012493.pub2">https://doi.org/10.1002/14651858.CD012493.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012493-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012493-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012493-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012493-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012493-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012493-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012493-abs-0001" lang="en"> <section id="CD012493-sec-0001"> <h3 class="title" id="CD012493-sec-0001">Background</h3> <p>Primary autoimmune haemolytic anaemia (AIHA) is an autoantibody mediated condition characterised by a variable disease course. A myriad of immunomodulatory agents have been employed but there is a paucity of evidence to support their use or compare their effectiveness. </p> </section> <section id="CD012493-sec-0002"> <h3 class="title" id="CD012493-sec-0002">Objectives</h3> <p>To determine the effects of various disease‐modifying treatment modalities in people with AHIHA. </p> </section> <section id="CD012493-sec-0003"> <h3 class="title" id="CD012493-sec-0003">Search methods</h3> <p>We searched MEDLINE (Ovid) (1946 to 2021), Embase (Ovid) (1974 to 2021), Latin American and Caribbean Health Sciences Literature (LILACS) (1982 to 2021), and the Cochrane Library (CENTRAL). Clinical trial registries and relevant conference proceedings were also reviewed. Records were included as of 7 March 2021. We did not impose any language restrictions. </p> </section> <section id="CD012493-sec-0004"> <h3 class="title" id="CD012493-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing immunosuppressive or immunomodulatory treatments against no treatment, placebo, or another immunosuppressive or immunomodulatory treatment, for people of all age with idiopathic AIHA. </p> </section> <section id="CD012493-sec-0005"> <h3 class="title" id="CD012493-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. The prioritised pre‐defined outcomes included complete haematological response at 12 months, frequency of adverse events at two, six and 12 months, partial haematological response at 12 months, overall survival at six and 12 months, relapse‐free survival (RFS) at six and 12 months, red blood cel (RBC) transfusion requirement after treatment at 12 months, and quality of life (QOL) as measured by validated instruments at 12 months. Based on data availability, we were only able to perform meta‐analysis on frequency of complete haematological response. </p> </section> <section id="CD012493-sec-0006"> <h3 class="title" id="CD012493-sec-0006">Main results</h3> <p>Two trials were included, enrolling a total of 104 adult participants (96 randomised) with warm AIHA in the setting of tertiary referral centres, both comparing the effectiveness between rituximab (375 mg/m<sup>2</sup> weekly for four weeks, or 1000 mg for two doses two weeks apart) plus glucocorticoid (prednisolone 1.5 or 1mg/kg/day with taper) and glucocorticoid monotherapy. The average age of participants in the two trials were 67 and 71, respectively. One of the included studies had good methodological quality with low risk of bias, whereas the other study had high risk of performance and detection bias due to lack of blinding. Compared with glucocorticoid alone, adding rituximab may result in a large increase of complete response at 12 months (n = 96, risk ratio (RR) 2.13, 95% confidence interval (CI) 1.34 to 3.40, GRADE: low‐certainty evidence). </p> <p>Rates of adverse effects at prespecified time‐points were not reported.</p> <p>Limited data on partial haematological response were reported. The evidence is very uncertain about the effect of adding rituximab to glucocorticoids on partial haematological response at 12 months (n = 32; study = 1; RR 3.00, 95% CI 0.13 to 68.57; GRADE very low‐certainty evidence). </p> <p>RBC transfusion need at 12 months was reported in one study, with four participants (mean number of packed red cell units 4.0 ± 2.82) from the rituximab group and five participants from the placebo (corticosteroid only) (mean number of packed red cell units 5.6 ± 4.15) group requiring transfusion, indicating very uncertain evidence about the effect of adding rituximab to glucocorticoids (n = 32, RR 0.80, 95% CI 0.26 to 2.45, GRADE very low‐certainty evidence). The other study did not report transfusion requirement at prespecified time points but reported no difference in transfusion requirement between the two groups when comparing responders from enrolment to end of response or to the end of study follow‐up (34 units versus 30 units, median [range]: 0 [1 to 6] versus 0 [1 to 5], P = 0·81). </p> <p>Overall survival and RFS rates at prespecified time‐points were not explicitly reported in either study. Data on QOL were not available. </p> </section> <section id="CD012493-sec-0007"> <h3 class="title" id="CD012493-sec-0007">Authors' conclusions</h3> <p>Available literature on the effectiveness of immunomodulatory therapy for primary AIHA is restricted to comparison between rituximab plus glucocorticoid and glucocorticoid alone, in patients with newly diagnosed warm AIHA, calling for need for additional studies. The current result suggests that combinatory therapy with rituximab and glucocorticoid may increase the rate of complete haematological response over glucocorticoid monotherapy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012493-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012493-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012493-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012493-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012493-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012493-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012493-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012493-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012493-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012493-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012493-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012493-abs-0002" lang="en"> <h3>Treatment for primary autoimmune haemolytic anaemia</h3> <p><b>What is primary autoimmune haemolytic anaemia (AIHA)?</b> </p> <p>Red blood cells carry oxygen to all parts of the body. In healthy people, red blood cells live about 120 days. In AIHA the immune system does not work properly and destroys red blood cells faster than rhe body can make them. Primary AIHA is when a person does not have another condition that caused their AIHA. </p> <p>Primary AIHA develops differently in different people. People often need to have repeated blood transfusions to keep their red blood cell levels normal. The disease may be life‐threatening for some people. </p> <p><b>What is the aim of this review and why is it important?</b> </p> <p>The aim of this review is to find out what research studies tell us about the <b>safety and effectiveness</b> of treating primary AIHA with immune modulating agents. <b>Immune modulating agents</b> change how your immune system works. They are not a cure, but they can slow AIHA. </p> <p>But how well do these agents work? Are some safer than others? The answers are important to help doctors and patients make treatment decisions based on evidence. </p> <p><b>What studies did the review find?</b> </p> <p>We looked at studies that were finished by 7 March 2021. We found two studies that looked at an immune modulating agent called rituximab, which targets immune cells, called B‐cells. </p> <p>The studies compared two groups of adults with primary AIHA who were treated:</p> <p>· with rituximab and steroid</p> <p>· with steroid alone</p> <p>It’s important to know that these studies were very small, including a total of 96 people. And the design of one study had a problem that may have affected the results. </p> <p><b><i>Recovery after treatment</i> </b> </p> <p>· <b>At 12 months after beginning treatment, rituximab and steroid appear to help more people recover from primary AIHA than steroid alone.</b> Researchers think the quality of this research finding is low. They think future research is likely to change these results. </p> <p>· At six months after beginning treatment, there was no difference in recovery between the adults treated with rituximab and a steroid and those treated with a steroid alone. </p> <p><b><i>Side effects from treatment</i> </b> </p> <p>· Side effects between the two groups were the same.</p> <p><b>What’s the bottom line of this review?</b> </p> <p>Rituximab and steroid <i>may</i> help more people have a complete recovery from newly diagnosed, primary warm AIHA than steroid alone. Side effects appear to be about the same for both treatments. But <b>more research is needed</b> to know for sure. </p> <p>Doctors offer other treatments for primary AIHA that may be helpful, but there is a lack of research about how well they work. For now, based on the little information we have, the patient and doctor will have to carefully make decisions together about treating primary AIHA. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012493-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012493-sec-0059"></div> <h3 class="title" id="CD012493-sec-0060">Implications for practice</h3> <section id="CD012493-sec-0060"> <p>The addition of rituximab to corticosteroid may improve complete response rate in adults with newly diagnosed warm, primary autoimmune haemolytic anaemia (AIHA), in comparison with the use of corticosteroid alone. There is a lack of high‐certainty evidence to support the use of other immunosuppressive therapy. </p> </section> <h3 class="title" id="CD012493-sec-0061">Implications for research</h3> <section id="CD012493-sec-0061"> <p>Further studies are required to consolidate the evidence for combining rituximab with corticosteroid in warm AIHA. In addition, high‐quality RCTs are needed to address the efficacy of the numerous immunosuppressive/immunomodulatory approaches in managing AIHA beyond rituximab. Studies should also target various populations based on patient age and differences in disease pathophysiology. Studies with adequate follow‐up, report on survival and quality of life (QOL) measures should be prioritised in such chronic conditions. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012493-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012493-sec-0008"></div> <div class="table" id="CD012493-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rituximab plus corticosteroid compared with corticosteroid (+/‐ placebo) for warm AIHA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with newly diagnosed warm AIHA </p> <p><b>Settings:</b> referral centres </p> <p><b>Intervention:</b> rituximab plus corticosteroid </p> <p><b>Comparison:</b> corticosteroid only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corticosteroid only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rituximab and corticosteroid only</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete haematological response at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.13</b> (1.34 to 3.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<b>#</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency of adverse events at two, six and 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The included studies did not report frequency of adverse events at two, six an 12 months </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Partial haematological response at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.00</b> (0.13 to 68.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>very low<b>$</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only reported by <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at six and 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The included studies did not report OS</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse‐free survival at six and 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The included studies did not report RFS at specific time points</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RBC transfusion requirement after treatment at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>313 per 1000</b> (mean number of packed red cell units 5.6 ± 4.15) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>250 per 1000</b> (mean number of packed red cell units 4.0 ± 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.80</b> (0.26 to 2.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only reported by <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>. The included studies did not report transfusion requirement at two and six months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QOL as measured by validated instruments at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The included studies did not report QOL measures</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>OS:</b> overall survival; <b>QoL:</b> quality of life; <b>RBC:</b> red blood cell; <b>RCT:</b> randomised controlled trial; ; <b>RFS:</b> relapse‐free survival<b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>#Evidence from RCT downgraded because of high risk of bias in study design and small sample size. </p> <p>$Evidence from RCT downgraded because of imprecision in results and small sample size.</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012493-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012493-sec-0009"></div> <section id="CD012493-sec-0010"> <h3 class="title" id="CD012493-sec-0010">Description of the condition</h3> <p>Autoimmune haemolytic anaemia (AIHA) is a condition characterised by the presence of autoantibodies which bind to surface of the patient's own red blood cells (RBCs) leading to premature destruction (<a href="./references#CD012493-bbs2-0055" title="GehrsBC , FriedbergRC . Autoimmune hemolytic anemia. American Journal of Hematology2002;69:258-71. [DOI: 10.1002/ajh.10062]">Gehrs 2002</a>). Such destruction of RBCs (haemolysis) can occur within the circulation (intravascular haemolysis) or within the spleen (extravascular haemolysis). Incidence of AIHA ranges from 0.8 to 3 new cases per 100,000 individuals per year, and the estimated prevalence is 17 per 100,000 individuals, more commonly occurring in individuals after 50 years of age (<a href="./references#CD012493-bbs2-0046" title="AladjidiN , LevergerG , LeblancT , PicatMQ , MichelG , BertrandY , et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica2011;96(5):655-63.">Aladjidi 2011</a>; <a href="./references#CD012493-bbs2-0053" title="EatonWW , RoseNR , KalaydjianA , PedersenMG , MortensenPB . Epidemiology of autoimmune diseases in Denmark. Journal of Autoimmunity2007;29(1):1-9.">Eaton 2007</a>; <a href="./references#CD012493-bbs2-0055" title="GehrsBC , FriedbergRC . Autoimmune hemolytic anemia. American Journal of Hematology2002;69:258-71. [DOI: 10.1002/ajh.10062]">Gehrs 2002</a>; <a href="./references#CD012493-bbs2-0063" title="KleinNP , RayP , CarpenterD , HansenJ , LewisE , FiremanB , et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine2010;28(4):1062-8.">Klein 2010</a>; <a href="./references#CD012493-bbs2-0072" title="SokolRJ , BookerDJ , StampsR . The pathology of autoimmune haemolytic anaemia. Journal of Clinical Pathology1992;45(12):1047.">Sokol 1992</a>). AIHA may run an acute or chronic course; severity of the condition can range from fully compensated disease to life‐threatening anaemia, and can be classified by the temperature reactivity of RBC autoantibodies, as well as by the underlying aetiology. Warm AIHA is the most common type; it is associated with autoantibodies, often immunoglobulin G (IgG), being most reactive at 37<sup>o</sup>C and can be secondary to rheumatological disorders and lymphoproliferative conditions. Haemolysis is usually extravascular and takes place in the spleen, with a disease course that is typically chronic and relapsing. Cold AIHA, on the other hand, is a result of autoantibodies, usually immunoglobulin M (IgM), with the highest affinity at 0<sup>o</sup>C to 4<sup>o</sup>C and can be associated with underlying lymphoproliferative conditions and infections (e.g. mycoplasma, Ebstein‐Barr virus). IgM causes complement fixation and results in intravascular haemolysis, which tends to be abrupt but self‐limiting. Paroxysmal cold haemoglobinuria is a rare subtype of cold AIHA caused by IgG that preferentially binds at a lower temperature, mostly in children following infections. Infrequently, mixed‐type AIHA may occur in an individual where a combination of warm and cold autoantibodies exist. Drug‐induced immune haemolytic anaemia is a distinct entity that may be associated with both warm and cold AIHA (<a href="./references#CD012493-bbs2-0061" title="JohnsonST , FuegerJT , GottschallJL . One center's experience: the serology and drugs associated with drug‐induced immune hemolytic anemia—a new paradigm. Transfusion2007;47(4):697-702.">Johnson 2007</a>). This review focuses on the treatment for primary, or idiopathic AIHA, where no underlying systemic disease can be identified. </p> <p>Diagnosis of primary AIHA depends on the demonstration of haemolysis, serologic evidence of autoantibody against the individual's own RBCs and exclusion of secondary causes (identifiable in 20% to 80% of cases) (<a href="./references#CD012493-bbs2-0055" title="GehrsBC , FriedbergRC . Autoimmune hemolytic anemia. American Journal of Hematology2002;69:258-71. [DOI: 10.1002/ajh.10062]">Gehrs 2002</a>). The direct antiglobulin test (DAT) is commonly used to demonstrate the presence of autoantibody‐coated patient RBCs, although it is important to bear in mind alternative causes for a positive DAT including the use of intravenous immunoglobulin, drug‐induced autoantibodies, haemolytic transfusion reaction, thalassaemia, sickle cell disease, and multiple myeloma (<a href="./references#CD012493-bbs2-0050" title="ClarkJA , TanleyPC , WallasCH . Evaluation of patients with positive direct antiglobulin tests and nonreactive eluates discovered during pretransfusion testing. Immunohematology1992;8(1):9-12.">Clark 1992</a>). Haemolysis on the other hand, is suggested clinically when yellowish discolouration of the skin (jaundice), together with pallor is detected, with or without the presence of enlargement of the spleen (splenomegaly). In terms of laboratory evaluation, complete blood count with peripheral smear, serum bilirubin, lactate dehydrogenase (LDH), haptoglobin, methaemalbumin and urine haemoglobin are useful in determining the presence and type of haemolysis (presence of schistocytes, low haptoglobin, raised methaemalbumin and urine haemoglobin in intravascular haemolysis; presence of spherocytes, raised unconjugated bilirubin in extravascular haemolysis). In warm AIHA, anti‐IgG anti‐sera is typically detected in DAT while in cold AIHA, anti‐C3d anti‐sera is usually present due to IgM‐mediated haemolysis. </p> <p>Individuals with AIHA may required immunomodulatory therapies and more than half of the people, especially those with severe anaemia and mixed serological type, may require multiple agents to achieve treatment response (<a href="./references#CD012493-bbs2-0047" title="BarcelliniW , FattizzoB , ZaninoniA , RadiceT , NicheleI , Di BonaE , et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood2014;124(19):2930-6.">Barcellini 2014</a>). They also experience morbidities including thrombosis, acute renal failure, infection and acute renal failure due to the disease itself and complications from immunomodulatory therapies including splenectomy. Between a quarter and half of all individuals who achieve remission might develop disease relapse (<a href="./references#CD012493-bbs2-0047" title="BarcelliniW , FattizzoB , ZaninoniA , RadiceT , NicheleI , Di BonaE , et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood2014;124(19):2930-6.">Barcellini 2014</a>). Non‐responders or those who relapse may be dependent on regular transfusions to alleviate the symptoms of anaemia. Estimated mortality due to AIHA is 3% to 4% (<a href="./references#CD012493-bbs2-0048" title="BarcelliniW , ZaninoniA , FattizzoB , GiannottaJA , LunghiM , FerrariA , et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. American Journal of Hematology2018;93:E243-6.">Barcellini 2018</a>). </p> </section> <section id="CD012493-sec-0011"> <h3 class="title" id="CD012493-sec-0011">Description of the intervention</h3> <p>Treatment depends on the severity of haemolysis. Supportive treatment including folic acid supplementation, red cell transfusion and avoidance of cold exposure in individuals with cold AIHA are not within the scope of the current review (<a href="./references#CD012493-bbs2-0055" title="GehrsBC , FriedbergRC . Autoimmune hemolytic anemia. American Journal of Hematology2002;69:258-71. [DOI: 10.1002/ajh.10062]">Gehrs 2002</a>). In AIHA with identifiable secondary causes, treatment should be targeted towards the underlying condition. </p> <p>Specific treatment for idiopathic AIHA includes immunosuppressive or immunomodulatory therapy. Traditionally, glucocorticoids (prednisolone 1 mg to 1.5 mg/kg/day for one to three weeks then tapered) are the first‐line therapy for people with AIHA with up to three quarters of people demonstrating improvement within three weeks. Relapse is nevertheless common (15% to 40%) after tapering of glucocorticoids in the first six months to one year, and thus the majority of people responding to glucocorticoids would have to be continued with a lower maintenance dose (<a href="./references#CD012493-bbs2-0046" title="AladjidiN , LevergerG , LeblancT , PicatMQ , MichelG , BertrandY , et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica2011;96(5):655-63.">Aladjidi 2011</a>; <a href="./references#CD012493-bbs2-0069" title="SankaranJ , RodriguezV , JacobEK , KreuterJD , GoRS . Autoimmune hemolytic anemia in children: Mayo Clinic Experience. Journal of Pediatric Hematology/Oncology2016;38(3):e120-4.">Sankaran 2016</a>; <a href="./references#CD012493-bbs2-0074" title="ZanellaA , BarcelliniW . Treatment of autoimmune hemolytic anemias. Haematologica2014;99:1547-54.">Zanella 2014</a>). Adverse effects from prolonged glucocorticoid use include Cushingoid changes, hypertension, hyperglycaemia, peptic ulcers, and reduced bone mineral density. Splenectomy has been considered the second‐line therapy for people failing glucocorticoid therapy. Response rates after splenectomy ranged from 60% to 75%, but carry the risk of thrombosis as well as infection due to encapsulated bacteria and parasites including malaria (<a href="./references#CD012493-bbs2-0051" title="DavidsonRN , WallRA . Prevention and management of infections in patients without a spleen. Clinical Microbiology and Infection2001;7(12):657-60.">Davidson 2001</a>; <a href="./references#CD012493-bbs2-0062" title="KatkhoudaN , HurwitzMB , RiveraRT , ChandraM , WaldrepDJ , GugenheimJ , et al. Laparoscopic splenectomy: outcome and efficacy in 103 consecutive patients. Annals of Surgery1998;228(4):568-78. [PMID: 9790346]">Katkhouda 1998</a>). </p> <p>In people with refractory disease, a number of interventions have been tested with various degree of success. These include immunosuppressive agents including cyclophosphamide, danazol, cyclosporine, and mycophenolate mofetil (<a href="./references#CD012493-bbs2-0057" title="HershkoC , SonnenblickM , AshkenaziJ . Control of steroid-resistant autoimmune haemolytic anemia by cyclosporine. British Journal of Haematology1990;76:436-7.">Hershko 1990</a>; <a href="./references#CD012493-bbs2-0060" title="HowardJ , HoffbrandAV , PrenticeHG , MehtaA . Mycophenolate mofetil for the treatment of refractory autoimmune haemolytic anemia and autoimmune thrombocytopenic purpura. British Journal of Haematology2002;117:712-5.">Howard 2002</a>; <a href="./references#CD012493-bbs2-0026" title="MoyoVM , SmithD , BrodskyI , CrilleyP , JonesRJ , BrodskyRA . High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood2002;100(2):704-6. ">Moyo 2002</a>; <a href="./references#CD012493-bbs2-0067" title="PignonJM , PoirsonE , RochantH . Danazol in autoimmune haemolytic anaemia. British Journal of Haematology1993;83:343-5.">Pignon 1993</a>), as well as monoclonal antibodies including anti‐CD20 (rituximab) and anti‐CD52 (alemtuzumab) (<a href="./references#CD012493-bbs2-0043" title="ZeccaM , NobiliB , RamenghiU , PerrottaS , AmendolaG , RositoP , et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood2003;101(10):3857-61. ">Zecca 2003</a>; <a href="./references#CD012493-bbs2-0049" title="CheungWW , HwangGY , TseE , KwongYL . Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica2006;91(Supp 5):ECR 13.">Cheung 2006</a>). With a response rate of 80% to 90%, rituximab is increasingly being used in people with AIHA failing glucocorticoids. Each medication possesses its own side effects which are detailed in the next section (<a href="./references#CD012493-bbs2-0049" title="CheungWW , HwangGY , TseE , KwongYL . Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica2006;91(Supp 5):ECR 13.">Cheung 2006</a>; <a href="./references#CD012493-bbs2-0057" title="HershkoC , SonnenblickM , AshkenaziJ . Control of steroid-resistant autoimmune haemolytic anemia by cyclosporine. British Journal of Haematology1990;76:436-7.">Hershko 1990</a>; <a href="./references#CD012493-bbs2-0060" title="HowardJ , HoffbrandAV , PrenticeHG , MehtaA . Mycophenolate mofetil for the treatment of refractory autoimmune haemolytic anemia and autoimmune thrombocytopenic purpura. British Journal of Haematology2002;117:712-5.">Howard 2002</a>; <a href="./references#CD012493-bbs2-0026" title="MoyoVM , SmithD , BrodskyI , CrilleyP , JonesRJ , BrodskyRA . High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood2002;100(2):704-6. ">Moyo 2002</a>; <a href="./references#CD012493-bbs2-0067" title="PignonJM , PoirsonE , RochantH . Danazol in autoimmune haemolytic anaemia. British Journal of Haematology1993;83:343-5.">Pignon 1993</a>, <a href="./references#CD012493-bbs2-0043" title="ZeccaM , NobiliB , RamenghiU , PerrottaS , AmendolaG , RositoP , et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood2003;101(10):3857-61. ">Zecca 2003</a>). Interventions targeted at removing circulating autoantibodies include intravenous immunoglobulin and plasma exchange (<a href="./references#CD012493-bbs2-0054" title="FloresG , Cunningham-RundlesC , NewlandAC , BusselJB . Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia; results in 73 patients. American Journal of Hematology1993;44(4):237-42.">Flores 1993</a>; <a href="./references#CD012493-bbs2-0071" title="SmithJW , WeinsteinR , HillyerKL . Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion2003;43:820-2.">Smith 2003</a>). Accessibility to the above measures may be limited in resource‐poor countries. </p> </section> <section id="CD012493-sec-0012"> <h3 class="title" id="CD012493-sec-0012">How the intervention might work</h3> <p>Immunosuppressive or immunomodulatory therapy interfere with the immune destruction of RBCs. </p> <p> <ol id="CD012493-list-0001"> <li> <p>Glucocorticoids inhibit Fc receptor‐mediated removal of sensitised RBCs, and in the longer term reduce production of autoantibodies (<a href="./references#CD012493-bbs2-0074" title="ZanellaA , BarcelliniW . Treatment of autoimmune hemolytic anemias. Haematologica2014;99:1547-54.">Zanella 2014</a>). </p> </li> <li> <p>Splenectomy removes a major site of RBC destruction and autoantibody production (<a href="./references#CD012493-bbs2-0074" title="ZanellaA , BarcelliniW . Treatment of autoimmune hemolytic anemias. Haematologica2014;99:1547-54.">Zanella 2014</a>). </p> </li> <li> <p>Rituximab is an anti‐CD20 monoclonal antibody given as four‐weekly intravenous infusions. The antibody targets and depletes host B cells, which are responsible for the generation of autoantibodies (<a href="./references#CD012493-bbs2-0043" title="ZeccaM , NobiliB , RamenghiU , PerrottaS , AmendolaG , RositoP , et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood2003;101(10):3857-61. ">Zecca 2003</a>). Side effects include infusion reactions, immunosuppression and hepatitis B reactivation. </p> </li> <li> <p>Alemtuzumab is an anti‐CD52 monoclonal antibody targeting CD52, which is an antigen expressed by mature lymphocytes. Lymphodepletion with alemtuzumab would effectively devoid the host's capability of autoantibody generation (<a href="./references#CD012493-bbs2-0049" title="CheungWW , HwangGY , TseE , KwongYL . Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica2006;91(Supp 5):ECR 13.">Cheung 2006</a>). Side effects include infusion reactions and immunosuppression. </p> </li> <li> <p>Cyclophosphamide is an alkylating agent with potent myelosuppressive effect. Lymphocytes are highly sensitive to the drug and depletion would disrupt the autoimmunity involved (<a href="./references#CD012493-bbs2-0026" title="MoyoVM , SmithD , BrodskyI , CrilleyP , JonesRJ , BrodskyRA . High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood2002;100(2):704-6. ">Moyo 2002</a>). Nausea, vomiting, alopecia, myelosuppression, haemorrhagic cystitis, and gonadal toxicity are potential adverse effects with the drug. </p> </li> <li> <p>Danazol is a semi‐synthetic androgen with immunomodulatory effect via decreasing IgG production and cell‐bound IgG and complement (<a href="./references#CD012493-bbs2-0067" title="PignonJM , PoirsonE , RochantH . Danazol in autoimmune haemolytic anaemia. British Journal of Haematology1993;83:343-5.">Pignon 1993</a>). Side effects include its androgenic effects and derangement in liver function. </p> </li> <li> <p>Cyclosporine is a calcineurin inhibitor that suppresses T helper cells activities, decreasing autoantibodies synthesis (<a href="./references#CD012493-bbs2-0057" title="HershkoC , SonnenblickM , AshkenaziJ . Control of steroid-resistant autoimmune haemolytic anemia by cyclosporine. British Journal of Haematology1990;76:436-7.">Hershko 1990</a>). Individuals should be monitored for hair growth, gum hypertrophy, renal impairment, hypertension and rarely, neurological complications. </p> </li> <li> <p>Mycophenolate mofetil (MMF) reversibly inhibits inosine monophosphate dehydrogenase and in turn inhibits purine synthesis required in the proliferation of B and T cells (<a href="./references#CD012493-bbs2-0060" title="HowardJ , HoffbrandAV , PrenticeHG , MehtaA . Mycophenolate mofetil for the treatment of refractory autoimmune haemolytic anemia and autoimmune thrombocytopenic purpura. British Journal of Haematology2002;117:712-5.">Howard 2002</a>). Adverse effects are gastrointestinal disturbances and myelosuppression. </p> </li> <li> <p>Use of intravenous immunoglobulin (IVIG) in AIHA is based on its effectiveness in immune thrombocytopenia, but its efficacy with AIHA is more controversial. The mechanism of action is hypothesised to be through competitive inhibition of autoantibody adsorption to patient blood cells, as well as by decreasing uptake of autoantibody‐coated blood cells by the reticuloendothelial system through blockage of macrophage Fc receptors (<a href="./references#CD012493-bbs2-0054" title="FloresG , Cunningham-RundlesC , NewlandAC , BusselJB . Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia; results in 73 patients. American Journal of Hematology1993;44(4):237-42.">Flores 1993</a>). Infusion reactions, fever, arthralgia, haemolysis, and aseptic meningitis are possible complications. </p> </li> <li> <p>Plasma exchange is usually reserved for people with fulminant AIHA. The process effectively removes host circulating immunoglobulins and complements that are responsible for the immune destruction of RBCs (<a href="./references#CD012493-bbs2-0071" title="SmithJW , WeinsteinR , HillyerKL . Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion2003;43:820-2.">Smith 2003</a>). Side effects are attributed to the insertion of the apheresis catheter, and the process of apheresis which may cause haemodynamic disturbances, hypocalcaemia and coagulopathy. </p> </li> </ol> </p> </section> <section id="CD012493-sec-0013"> <h3 class="title" id="CD012493-sec-0013">Why it is important to do this review</h3> <p>Various immunosuppressive medications and other specific treatment modalities are available for the management of idiopathic AIHA. As an uncommon condition, it remains uncertain whether high‐quality evidence exists to support any treatment regimen and what the more effective regimens are. This systematic review will provide an evidence base for the selection of immunomodulatory treatment that most likely benefits people with idiopathic AIHA. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012493-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012493-sec-0014"></div> <p>To determine the effectiveness and safety of various disease‐modifying treatment modalities in people with autoimmune haemolytic anaemia (AIHA). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012493-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012493-sec-0015"></div> <section id="CD012493-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012493-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled trials (RCTs).</p> </section> <section id="CD012493-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included male and female participants of all ages suffering from idiopathic AIHA. Individuals with newly diagnosed, relapsing or refractory disease; warm or cold AIHA were included. Studies on people with secondary AIHA were excluded. There was no limitation on study settings. </p> </section> <section id="CD012493-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials evaluating specific, immunosuppressive or immunomodulatory treatments for AIHA, encompassing but not limited to: corticosteroids, intravenous immunoglobulin (IVIG), rituximab, alemtuzumab, azathioprine, cyclosporine, mycophenolate mofetil (MMF), plasma exchange and splenectomy. We excluded trials of supportive treatment such as folic acid supplement and transfusion alone. The control interventions could be another specific treatment,supportive treatment alone, placebo treatment, or no treatment. We also included trials comparing different dosing regimens of the same treatment. </p> </section> <section id="CD012493-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the outcomes listed below as criteria for study inclusion.</p> <section id="CD012493-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012493-list-0002"> <li> <p>Frequency of complete haematological response (complete response (CR), defined as normalisation of haemoglobin concentration, reticulocyte count, and indirect (or unconjugated] bilirubin level) at months two, six and 12. </p> </li> <li> <p>Frequency of adverse events at two, six and 12 months.</p> </li> </ol> </p> </section> <section id="CD012493-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012493-list-0003"> <li> <p>Frequency of partial haematological response (partial response (PR), defined as improvement in haemoglobin concentration) at two, six and 12 months </p> </li> <li> <p>RBC transfusion requirement after treatment (measured as units of RBCs transfused per month or millilitres (mL) per kg body weight) at two, six and 12 months </p> </li> <li> <p>Frequency of direct antiglobulin test (DAT) positivity after treatment at two, six and 12 months </p> </li> <li> <p>Overall survival at six and 12 months</p> </li> <li> <p>Relapse‐free survival (RFS) at six and 12 months</p> </li> <li> <p>Frequency of relapse at six and 12 months</p> </li> <li> <p>Quality of life (QOL) as measured by validated instruments at 12 months</p> </li> </ol> </p> </section> </section> </section> <section id="CD012493-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012493-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched MEDLINE (Ovid) (1946 to 2021) (<a href="./appendices#CD012493-sec-0065">Appendix 1</a>), EMBASE (Ovid) (1974 to 2021) (<a href="./appendices#CD012493-sec-0066">Appendix 2</a>), LILACS (Latin American and Caribbean Health Sciences Literature) (1982 to 2021) (<a href="./appendices#CD012493-sec-0067">Appendix 3</a>), and Cochrane Library (CENTRAL) (latest issue) (<a href="./appendices#CD012493-sec-0068">Appendix 4</a>). The search strategies for the different electronic databases using a combination of controlled vocabulary and text word terms are shown in the appendices (<a href="./appendices#CD012493-sec-0065">Appendix 1</a>; <a href="./appendices#CD012493-sec-0066">Appendix 2</a>; <a href="./appendices#CD012493-sec-0067">Appendix 3</a>; <a href="./appendices#CD012493-sec-0068">Appendix 4</a>). </p> <p>We did not incorporate search in the China Journal Net database (search date 7 March 2021) after submission of the protocol (<a href="./references#CD012493-bbs2-0065" title="LiuAP , CheukDK . Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD012493. [DOI: 10.1002/14651858.CD012493]">Liu 2017</a>) due to the extreme brevity of full‐text articles published which made interpretation of both quality and results impractical. </p> </section> <section id="CD012493-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the following clinical trial registries on the Internet using the search terms " haemolytic anaemia" or "hemolytic anemia": </p> <p> <ol id="CD012493-list-0004"> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/)</p> </li> <li> <p>United States Clinical Trials Registry (https://clinicaltrials.gov/)</p> </li> <li> <p>European Union Clinical Trial Register (http://www.clinicaltrialsregister.eu/)</p> </li> </ol> </p> <p>We also searched conference proceedings of the following scientific meetings using the search terms " haemolytic anaemia" or "hemolytic anemia" and "trials": </p> <p> <ol id="CD012493-list-0005"> <li> <p>Annual Meeting of American Society of Haematology (ASH) (2004 to 2021)</p> </li> <li> <p>Annual Congress of the European Haematology Association (EHA) (2006 to 2021).</p> </li> </ol> </p> <p>We searched reference lists of relevant articles identified in all the searches. We contacted authors of included studies to enquire about additional studies. We did not apply any language restriction in our searches. </p> </section> </section> <section id="CD012493-sec-0026"> <h3 class="title" id="CD012493-sec-0026">Data collection and analysis</h3> <section id="CD012493-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Both review authors independently examined identified studies to select studies meeting the inclusion criteria. Discrepancies were resolved by discussion. We reported the flow of studies as per the PRISMA statement in a flow chart (<a href="./references#CD012493-bbs2-0066" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine2009;151(4):264-9.">Moher 2009</a>), which included data on the number of records identified through database searching, number of additional records identified through other sources, number of records after duplicates removed, number of records screened, number of records excluded, number of full‐text articles examined for eligibility, number of full‐text articles excluded with reasons, and numbers of studies included in qualitative and quantitative syntheses (<a href="./references#CD012493-bbs2-0058" title="HigginsJP , DeeksJJ , editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011a</a>); see <a href="#CD012493-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012493-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012493-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012493-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Both review authors independently extracted data using a standardised data collection form (<a href="./references#CD012493-bbs2-0058" title="HigginsJP , DeeksJJ , editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011a</a>). We extracted data on study design and methods including study dates, location, setting, type of study (parallel group or cross‐over or other designs), stratified randomisation variables, random sequence generation, allocation concealment, and blinding methods. We extracted data on participant inclusion and exclusion criteria, number of participants in each intervention and control group, and for each group, their demographics (age, sex, ethnicity), baseline laboratory parameters (haemoglobin level, reticulocyte count, bilirubin level, direct anti‐globulin test (DAT) positivity), baseline transfusion requirements, associated conditions and comorbidities, and previous intervention received (drug and regimen). We extracted data on details of intervention for each group, and dropouts of each group and follow‐up duration. We extracted outcomes measured in each study that matched with our pre‐specified outcomes. No transformation of reported data was required. We also extracted data on funding source and declaration of interests. Data were entered into Review Manager software (RevMan 5.3) (<a href="./references#CD012493-bbs2-0068" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) by one review author (APYL) and checked by the other review author (DKLC). </p> </section> <section id="CD012493-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Both review authors independently assessed the risk of bias of included studies with the Cochrane 'Risk of bias' tool (<a href="./references#CD012493-bbs2-0059" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011b</a>). The following domains were assessed: random sequence generation, allocation concealment, blinding of participants, study personnel and outcome assessors, incomplete outcome data, selective reporting, and other sources of bias. For each domain for each study, the risk of bias was graded as "high", "unclear" or "low" according to the criteria stated in the <i>Cochrane</i> <i>Handbook for Systematic Reviews of Interventions</i>. Discrepancies between the review authors were resolved by discussion. </p> </section> <section id="CD012493-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We estimated risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes. We used hazard ratio (HR) with 95% CI for time‐to‐event outcomes and planned to use mean difference (MD) with 95% CIs for continuous outcomes. For continuous outcomes using different scales (e.g. quality of life (QoL) data), we planned to use standardised mean difference (SMD) with 95% CI (<a href="./references#CD012493-bbs2-0052" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). </p> </section> <section id="CD012493-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to use appropriate unit of analysis for cluster‐randomised trials and cross‐over trials according to the <i>Cochrane</i> <i>Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012493-bbs2-0052" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>), if these types of trials had been found and included. </p> </section> <section id="CD012493-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We requested missing data from the corresponding authors of included studies (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>; <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) and nonetheless failed to acquire additional information with no response received. We included all participants with intention‐to‐treat (ITT) analyses. </p> </section> <section id="CD012493-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to evaluate the degree of heterogeneity of treatment effects. We followed the guide on interpretation of the I<sup>2</sup> statistic suggested by the <i>Cochrane</i> <i>Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012493-bbs2-0052" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>) as follows: </p> <p> <ol id="CD012493-list-0006"> <li> <p>0% to 40%: may not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ol> </p> <p>We also used the Chi<sup>2</sup> test of homogeneity to assess the strength of evidence regarding heterogeneity. </p> </section> <section id="CD012493-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias using a funnel plot (estimated differences in treatment effects against their standard errors) in case 10 or more studies are identified for a given outcome, although this was not probable as only two studies were included (<a href="./references#CD012493-bbs2-0073" title="SterneJA , EggerM , MoherD , editor(s). Chapter 10: Addressing reporting biases. In Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Sterne 2011</a>). </p> </section> <section id="CD012493-sec-0035"> <h4 class="title">Data synthesis</h4> <p>With the assumption that the different studies would likely be estimating different, yet related, intervention effects, we used the random‐effects model for meta‐analysis to obtain the mean effect across studies(<a href="./references#CD012493-bbs2-0052" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). In case different interventions are identified in future updates, they will be summarised individually. Analysis was performed using Cochrane's statistical package Review Manager (RevMan 5.3) (<a href="./references#CD012493-bbs2-0068" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> </section> <section id="CD012493-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses (<a href="./references#CD012493-bbs2-0052" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>) for the following subgroups as they may have different prognosis and response to treatment (different size of treatment effect). </p> <p> <ol id="CD012493-list-0007"> <li> <p>Different age groups (children &lt; 18 years or adults &gt;= 18 years).</p> </li> <li> <p>With or without associated conditions (such as thrombocytopenia or neutropenia, or other autoimmune phenomena). </p> </li> <li> <p>Different degrees of anaemia (transfusion dependent or transfusion independent).</p> </li> <li> <p>Newly diagnosed versus refractory disease.</p> </li> </ol> </p> <p>We also planned to assess subgroup differences by examining the I<sup>2</sup> statistic and performing a Chi<sup>2</sup> test for homogeneity across subgroup results. In case heterogeneity was present, we planned to investigate the probable reasons for heterogeneity by examining the distribution of important participant factors between trials (age, associated conditions, degrees of anaemia, and previous interventions) and trial factors (randomisation concealment, blinding, dropouts, intervention regimens). </p> <p>As the above are currently not applicable based on the studies included, we will perform the above analyses in future updates as necessary. </p> </section> <section id="CD012493-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis to assess the impact of excluding studies with high risk of bias (<a href="./references#CD012493-bbs2-0052" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). We also planned to perform sensitivity analysis to assess the impact of excluding studies with significant amount (&gt; 30%) of missing outcome data. </p> </section> <section id="CD012493-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We produced a 'Summary of findings' table according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012493-bbs2-0052" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). The pre‐defined outcomes included were: </p> <p> <ul id="CD012493-list-0008"> <li> <p>frequency of complete haematological response (defined as normalisation of haemoglobin concentration, reticulocyte count, and indirect bilirubin level) at months two, six and 12 months; </p> </li> <li> <p>frequency of adverse events at two, six and 12 months;</p> </li> <li> <p>overall survival at six and 12 months;</p> </li> <li> <p>relapse‐free survival at six and 12 months;</p> </li> <li> <p>RBC transfusion requirement after treatment (measured as units of red cells transfused per month or mL per kg body weight) at two, six and 12 months; and </p> </li> <li> <p>QOL as measured by validated instruments at 12 months.</p> </li> </ul> </p> <p>These tables summarised the results for the prioritised pre‐defined outcomes, namely:</p> <p> <ul id="CD012493-list-0009"> <li> <p>complete haematological response at 12 months;</p> </li> <li> <p>frequency of adverse events at two, six and 12 months;</p> </li> <li> <p>partial haematological response at 12 months;</p> </li> <li> <p>overall survival at six and 12 months;</p> </li> <li> <p>relapse‐free survival at six and 12 months,</p> </li> <li> <p>RBC transfusion requirement after treatment at 12 months; and</p> </li> <li> <p>QOL as measured by validated instruments at 12 months;</p> </li> </ul> </p> <p>and provide grading of the certainty of evidence for each outcome according to the GRADE system as recommended by the <i>Cochrane</i> <i>Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012493-bbs2-0056" title="GRADE Working GroupGRADEpro. Version 3.2 for Windows. BrozekJL , OxmanA , ShünnemanH . GRADE Working Group, 2008.">GRADEpro 2008</a>; <a href="./references#CD012493-bbs2-0064" title="LefebvreC , ManheimerE , GlanvilleJ , editor(s). Chapter 6: Searching for studies. In Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Lefebvre 2011</a>; <a href="./references#CD012493-bbs2-0070" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www-cochrane-handbook.org.">Schünemann 2011</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012493-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012493-sec-0039"></div> <section id="CD012493-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD012493-sec-0041"> <h4 class="title">Results of the search</h4> <p>We obtained a total of 11980 results from the electronic search of the databases, after de‐duplication, 10610 articles remained. We screened the titles and abstracts of these against the inclusion and exclusion criteria for study selection and excluded 10564 references based on titles or abstracts alone. We obtained the full texts of the remaining 46 articles and assessed for eligibility. Two studies fulfilled the inclusion criteria and were included in the review (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>), with one secondary citation to an included study also identified (Michel 2015). The flow of records is summarised in <a href="#CD012493-fig-0001">Figure 1</a>. </p> </section> <section id="CD012493-sec-0042"> <h4 class="title">Included studies</h4> <p>Two studies were included (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) with details summarised in the ‘<a href="./references#CD012493-sec-0077" title="">Characteristics of included studies</a>’ table. Both trials were multi‐centre, Phase III randomised controlled trials (RCTs) comparing the efficacy of rituximab plus glucocorticoid versus glucocorticoid monotherapy in adults with warm, primary, autoimmune haemolytic anaemia (AIHA). </p> <p>In the study by Birgens and colleagues (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>), 65 participants with newly diagnosed warm AIHA (steroid use for &lt;1 week was allowed) were recruited in eight haematological centres in Denmark between March 2005 and June 2012. With one patient withdrawing before randomisation (1:1 using pre‐coded envelopes), 32 were randomised to receive rituximab plus glucocorticoid (12 females [37.5%], median age [range] = 65 [41‐89]) and 32 to receive glucocorticoid monotherapy (15 females [46.9%], median age [range] = 67 [35‐90]. All participants received oral prednisolone 1·5 mg/kg/day for two weeks followed by tapering according to this schedule: 0·75 mg/kg/day for one week (week three), thereafter 0·5 mg/kg/day for one week (week four), followed by a gradual reduction over the next four to eight weeks to the lowest dose that was effective in maintaining a normal haemoglobin level. In the group allocated to a combination of prednisolone and rituximab, rituximab was given at a dosage of 375 mg/m<sup>2</sup> as an intravenous infusion once a week for four weeks. The primary objective of the study was to analyse differences in treatment responses between the two groups. Responses were evaluated at three, six and 12 months after treatment was initiated. Complete response (CR) was defined as normalisation in haemoglobin concentration without any ongoing immunosuppressive treatment and without any biochemical signs of haemolytic activity. Partial response (PR) was defined as being similar to CR but requiring continued low‐dose prednisolone (&lt; 10 mg/day), or appearing as compensated haemolytic anaemia entailing a stable, acceptable haemoglobin level without any need of treatment except &lt; 10 mg/day prednisone. Secondary objectives were to evaluate differences in relapse‐free survival (RFS), red blood cell transfusion requirement after treatment, the need for splenectomy, and safety profiles associated with the treatments up to 12 months after enrolment. This trial was investigator‐initiated but was supported in part by research funding from Roche A/S, Denmark. The design of the study, protocol writing, interpretation of the data, and preparation of the manuscript were conducted without any interference from Roche. </p> <p>In the study by Michel and colleagues (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>), 39 participants with newly diagnosed warm AIHA (steroid use for &lt; 6 weeks was allowed) were screened from 13 centres in France from 2011 to 2015. Thirty‐two participants were randomised to receive rituximab (n = 16) or placebo (n = 16) (17 females [53%], mean age at inclusion 71  ±  16 years) on top of glucocorticoid therapy in a double‐blind manner. At inclusion, all participants received oral prednisone at a daily dose of 1 mg/kg for two weeks, and then tapered according to a pre‐defined recommended reduction scheme. Besides prednisone, randomised participants received two infusions of rituximab or placebo at a fixed dose of 1000 mg two weeks apart. The primary endpoint was overall response rate (CR + PR) in anITT analysis at one year. CR in this study was defined as a haemoglobin (Hb) level ≥ 11 g/dL (women) or ≥ 12 g/dL (men) without features of ongoing haemolysis (including normal haptoglobin level), without any ongoing treatment for warm AIHA on two different occasions four weeks apart in the absence of any recent transfusion. PR was defined as Hb level ≥ 10g/dL with at least a 2 g increase from baseline (i.e. at warm AIHA diagnosis) without any other treatment than prednisone given at a daily dose 10 mg or recent transfusion. Secondary objectives were PR, cumulative dose of steroids, and number of transfusions and hospitalisations at one year and incidence and severity of adverse events in both groups and CR/PR at two years. This study was promoted by the Direction de la Recherche Clinique, Assistance Publique‐Hôpitaux de Paris and supported by the Etablissement Français du Sang and by Roche. </p> <p>The median observation time was not reported in either study.</p> </section> <section id="CD012493-sec-0043"> <h4 class="title">Excluded studies</h4> <p>The current review excluded 41 studies as they were not RCTs in design (<a href="./references#CD012493-bbs2-0003" title="AbdwaniR , ManiR . Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. Lupus2009;18(5):460-4. ">Abdwani 2009</a>; <a href="./references#CD012493-bbs2-0004" title="AlmomenA , AleemA , HasanatoR , Al SalehK , AnjumF . Efficacy of rituximab in autoimmune hemolytic anemia. Haematologica2013;1:706. ">Almomen 2013</a>; <a href="./references#CD012493-bbs2-0005" title="AqrabawiHE . 762 The use of pentaglobulin in neonatal immune hemolytic anaemia. In: Archives of Disease in Childhood. Vol. 97. 2012:A219-20. ">Aqrabawi 2012</a>; <a href="./references#CD012493-bbs2-0006" title="AqrabawiHE . The use of pentaglobulin in neonatal immune hemolytic anaemia. Rawal Medical Journal2013;38(1):64-5. ">Aqrabawi 2013</a>; <a href="./references#CD012493-bbs2-0007" title="BarcelliniW , ZajaF , ZaninoniA , ImperialiFG , BattistaML , Di BonaE , et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood2012;119(16):3691-7. ">Barcellini 2012</a>; <a href="./references#CD012493-bbs2-0008" title="BarcelliniW , ZajaF , ZaninoniA , ImperialiFG , Di BonaE , FattizzoB , et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. European Journal of Haematology2013;91(6):546-51. ">Barcellini 2013</a>; <a href="./references#CD012493-bbs2-0009" title="BartkoJ , DerhaschnigU , GilbertJ , PanickerS , D'SaS , JagerU , et al. Safety and efficacy of the C1s complement inhibitor TNT009 in a first-inhuman trial. Clinical Therapeutics2017;39(8):e6-7. ">Bartko 2017</a>; <a href="./references#CD012493-bbs2-0010" title="BartkoJ , SchoergenhoferC , SchwameisM , FirbasC , BeliveauM , ChangC , et al. A randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway. Clinical Pharmacology and Therapeutics2018;104(4):655-63. ">Bartko 2018</a>; <a href="./references#CD012493-bbs2-0011" title="BerentsenS , RandenU , OksmanM , BirgensH , TvedtTH , DalgaardJ , et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood2017;130(4):537‐41. ">Berentsen 2017</a>; <a href="./references#CD012493-bbs2-0012" title="BerentsenS , RandenU , OksmanM , BirgensH , TvedtTH , DalgaardJ , et al. Bendamustine and rituximab combination therapy for cold agglutinin disease: results of a prospective Nordic trial. In: Haematologica. Vol. 102. 2017:241. ">Berentsen 2017a</a>; <a href="./references#CD012493-bbs2-0013" title="ChoudhryVP , PassiGR , PatiHP . Clinico-hematological spectrum of auto-immune hemolytic anemia: an Indian experience. Journal of the Association of Physicians of India1996;44(2):112-4. ">Choudhry 1996</a>; <a href="./references#CD012493-bbs2-0014" title="CrickxE , PoullotE , MoulisG , GoulabchandR , FieschiC , GalicierL , et al. Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. European Journal of Haematology2019;103(1):35-42. ">Crickx 2019</a>; <a href="./references#CD012493-bbs2-0015" title="DierickxD , KentosA , DelannoyA . The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood2015;125(21):3223-9. ">Dierickx 2015</a>; <a href="./references#CD012493-bbs2-0016" title="HeidelF , LipkaDB , vonAuerC , HuberC , ScharrerI , HessG . Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thrombosis &amp; Haemostasis2007;97(2):228-33. ">Heidel 2007</a>; <a href="./references#CD012493-bbs2-0017" title="HillA , HillQA . Autoimmune hemolytic anemia. Hematology-American Society of Hematology Education Program2018;2018(1):382-9. ">Hill 2018</a>; <a href="./references#CD012493-bbs2-0018" title="JagerU . AGMT-AIHA-Reg: PATIENT REGISTRY Autoimmune Hemolytic Anemia (AIHA) with corresponding biobank. In: Memo - Magazine of European Medical Oncology. Vol. 10. 2017:S41-2. ">Jager 2017</a>; <a href="./references#CD012493-bbs2-0019" title="JilmaB , GilbertJC , PanickerS , ParryGC , FillitzM , ThomasS , et al. Chronic inhibition of complement C1s By TNT009 produces sustained, complete remission in patients with severe, transfusion-dependent cold agglutinin disease (CAD). Blood2016;128(22):2435. ">Jilma 2016</a>; <a href="./references#CD012493-bbs2-0020" title="Lehrer-GraiwerJ , HemmawayC , HowardJ , TelferP , LaytonM , AwogbadeM , et al. GBT440, a novel HBS polymerization inhibitor, increases HB oxygen affinity and results in a rapid improvement in hemolysis and anemia. Haematologica2016;101 (Supplement 1)(Supp 1):125. ">Lehrer‐Graiwer 2016</a>; <a href="./references#CD012493-bbs2-0021" title="LiH , JiJ , DuY , HuangY , GuH , ChenM , WuR , HanB . Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study. Experimental Hematology2020;89:87-95. ">Li 2020</a>; <a href="./references#CD012493-bbs2-0022" title="LiuH , ShaoZ , JingL . The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome. Zhonghua Xue Ye Xue Za Zhi [Chinese Journal of Hematology]2001;22(11):581‐3. ">Liu 2001</a>; <a href="./references#CD012493-bbs2-0023" title="MehmoodT , TaylorM , WintersJL . Management of thrombotic microangiopathic hemolytic anemias with therapeutic plasma exchange: when it works and when it does not. Hematology - Oncology Clinics of North America2016;30(3):679-94. ">Mehmood 2016</a>; <a href="./references#CD012493-bbs2-0024" title="Miano, M, Ramenghi, U, Russo, G, Rubert, L, Barone, A, Tucci, F, et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. British Journal of Haematology2016;175:490-5. ">Miano 2016</a>; <a href="./references#CD012493-bbs2-0025" title="MottoDG , WilliamsJA , BoxerLA . Rituximab for refractory childhood autoimmune hemolytic anemia. Israel Medical Association Journal2002;4(11):1006-8. ">Motto 2002</a>; <a href="./references#CD012493-bbs2-0026" title="MoyoVM , SmithD , BrodskyI , CrilleyP , JonesRJ , BrodskyRA . High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood2002;100(2):704-6. ">Moyo 2002</a>; <a href="./references#CD012493-bbs2-0027" title="OsterborgA , KarlssonC , LundinJ . Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports2009;4(1):47-53. ">Osterborg 2009</a>; <a href="./references#CD012493-bbs2-0028" title="PanickerS , DruckerC , HussainS , ParryGC , GilbertJC , JilmaB , et al. TNT009 prevents erythrocyte c3 fragment opsonization and rescues reticulocytes from destruction in patients with cold agglutinin disease. In: Blood. Vol. 128. 2016:94. ">Panicker 2016</a>; <a href="./references#CD012493-bbs2-0029" title="PanickerS , ParryGC , FillitzM , SchenkT , SillaberC , BartkoJ , et al. TNT009, a monoclonal antibody inhibitor of C1s, induces a rapid and complete remission of anemia in primary cold agglutinin disease patients. Immunobiology2016;221(10):117-1. ">Panicker 2016a</a>; <a href="./references#CD012493-bbs2-0030" title="RaiMP , LeeEJ , BusselJB . Rituximab (RITUX) maintenance infusions in immune thrombocytopenia (ITP) to prolong remission following relapse after initial Ritux induction but responded to a second course. In: Blood. Vol. 132. 2018:3753. ">Rai 2018</a>; <a href="./references#CD012493-bbs2-0031" title="RaschettiR , CaimmiD , LambotteO , RodiereM , JeziorskiE . Severe refractory auto-immune hemolytic anemia treated with a chemiotherapy protocol. Allergy2012;67(Supp 96):649. ">Raschetti 2012</a>; <a href="./references#CD012493-bbs2-0032" title="ReynaudQ , DurieuI , DutertreM , LedochowskiS , DuruptS , MichalletAS , et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmunity Reviews2015;14(4):304-13. ">Reynaud 2015</a>; <a href="./references#CD012493-bbs2-0033" title="RiceHE , CrarySE , LangerJC , KemperAR . Comparative effectiveness of different types of splenectomy for children with congenital hemolytic anemias. Journal of Pediatrics2012;160(4):684-9. ">Rice 2012</a>; <a href="./references#CD012493-bbs2-0034" title="RodrigoC , RajapakseS , GooneratneL . Rituximab in the treatment of autoimmune haemolytic anaemia. British Journal of Clinical Pharmacology2015;79(5):709-19. ">Rodrigo 2015</a>; <a href="./references#CD012493-bbs2-0035" title="RossiG , GramegnaD , PaoloniF , FattizzoB , BindaF , D'AddaM , et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood2018;132(5):547-50. ">Rossi 2018</a>; <a href="./references#CD012493-bbs2-0036" title="RothA , BommerM , HuttmannA , Herich-TerhurneD , KuklikN , RekowskiJ , et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Advances2018;2(19):2543-9. ">Roth 2016</a>; <a href="./references#CD012493-bbs2-0037" title="ShahB . Darbepoetin in cancer related anemia. In: Indian Journal of Hematology and Blood Transfusion. Vol. 29. 2013:270-1. ">Shah 2013</a>; <a href="./references#CD012493-bbs2-0038" title="WangSW , ChengTT . Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin A: a case report. Lupus2005;14(6):483-5. ">Wang 2005</a>; <a href="./references#CD012493-bbs2-0039" title="WilliamsO , BhatR , BadawySM . Sirolimus for treatment of refractory primary warm autoimmune hemolytic anemia in children. Blood Cells Molecules &amp; Diseases2020;83:102427. ">Williams 2020</a>; <a href="./references#CD012493-bbs2-0040" title="YangN , WangB , GaoF , HuangXY , ZhaoXL , WangYY , ZhangXP . Evaluation of Efficacy and Safety of Blood Transfusion and Hormone Therapy in 40 Patients with Autoimmune Hemolytic Anemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi2020;28(4):1307-1311. ">Yang 2020</a>; <a href="./references#CD012493-bbs2-0041" title="ZajaF , IaconaI , MasoliniP , RussoD , SperottoA , ProsdocimoS , et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica2002;87(2):189-95. ">Zaja 2002</a>; <a href="./references#CD012493-bbs2-0042" title="ZanellaA , BarcelliniW . Autoimmune hemolytic anemia. In: Haematologica. Vol. 98. 2013:252-5. ">Zanella 2013</a>; <a href="./references#CD012493-bbs2-0043" title="ZeccaM , NobiliB , RamenghiU , PerrottaS , AmendolaG , RositoP , et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood2003;101(10):3857-61. ">Zecca 2003</a>). Two ongoing RCTs on the use of fostamatinib (oral spleen tyrosine kinase inhibitor) and M281 (human, anti‐neonatal Fc receptor antibody) respectively for warm AIHA are identified but excluded from the current analysis (<a href="./references#CD012493-bbs2-0044" title="CooperN , NumerofRP , TongS , KuterDJ . Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia (WAIHA): A phase 3, randomized, double-blind, placebo-controlled, global study. Blood2020;136(Supp 1):1-3. ">Cooper 2020</a>; <a href="./references#CD012493-bbs2-0045" title="Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia. clinicaltrials.gov/show/NCT04119050. ">NCT04119050</a>). </p> </section> </section> <section id="CD012493-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>One of the two included studies (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) had good methodological quality with low risk of bias in all areas; the other study (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>) had high risk of performance and detection bias due to lack of blinding, but otherwise low risk in other areas. These findings are summarised in the table <a href="./references#CD012493-sec-0077" title="">Characteristics of included studies</a> and <a href="#CD012493-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012493-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012493-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012493-sec-0045"> <h4 class="title">Allocation</h4> <p>Both included trials involved random allocation of participants, using pre‐coded envelops (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>) and central computer randomisation (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>), respectively. </p> </section> <section id="CD012493-sec-0046"> <h4 class="title">Blinding</h4> <p>Blinding was not performed in the study by Birgens and colleagues (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>). </p> </section> <section id="CD012493-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>There were no dropouts in both included studies (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>). </p> </section> <section id="CD012493-sec-0048"> <h4 class="title">Selective reporting</h4> <p>All predefined outcomes were accounted for in both included studies (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>); there was no evidence of selective reporting. </p> </section> <section id="CD012493-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were identified.</p> </section> </section> <section id="CD012493-sec-0050"> <h3 class="title" id="CD012493-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD012493-tbl-0001"><b>Summary of findings 1</b> Summary of findings</a> </p> <p>Both included studied compared rituximab plus corticosteroid compared with corticosteroid alone (+/‐ placebo) and were combined in a meta‐analysis. All effect sizes were calculated with the fixed‐effect model unless otherwise specified. See <a href="./full#CD012493-tbl-0001">summary of findings Table 1</a> for further details. </p> <section id="CD012493-sec-0051"> <h4 class="title">Primary outcome</h4> <p><b>Frequency of complete haematological response (defined as normalisation of haemoglobin (Hb) concentration, reticulocyte (immature red blood cells (RBCs)) count, and indirect (or unconjugated] bilirubin level) at months two, six and 12.</b> </p> <p>Compared with glucocorticoid alone, the evidence is very uncertain about the effect of adding rituximab to glucocorticoids on complete haematological response at six months (n = 64, study = 1; RR 1.73, 95% CI 0.99 to 3.02; participants = 64; RR and CI calculated by review authors; GRADE very low certainty), but it may result in a large increase of complete response at 12 months (n = 96; studies = 2; pooled RR 2.13, 95% CI 1.34 to 3.40; I<sup>2</sup> = 0%; GRADE low certainty) (<a href="#CD012493-fig-0003">Figure 3</a>, <a href="#CD012493-tbl-0002">Table 1</a>). No heterogeneity was observed. Both trials (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) did not report complete response rate at two months and one study (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) did not report response at six months. </p> <div class="figure" id="CD012493-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Rituximab with steroid versus steroid, outcome: 1.1 Complete haematological response at 12 months." data-id="CD012493-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rituximab with steroid versus steroid, outcome: 1.1 Complete haematological response at 12 months. </p> </div> </div> </div> <div class="table" id="CD012493-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Primary outcome ‐ complete haematological response</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Number of participants with complete response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Rituximab+corticosteroid</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Corticosteroid only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a> </p> <p>(n = 64 randomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a> </p> <p>(n = 32 randomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> </tbody> </table> </div> <p><b>Frequency of adverse events at two, six and 12 months.</b> </p> <p>Both studies (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) did not report adverse effects at the specified time points. </p> <p>Cumulative adverse effects and serious adverse events with a non‐fatal or fatal outcome did not differ between the two groups in the study by Birgens and colleagues (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="#CD012493-tbl-0003">Table 2</a>). The study by Michel and colleagues (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) described no post‐infusion reactions in both groups, but four and 10 episodes of severe adverse events in participants who received rituximab with corticosteroid and corticosteroid alone, respectively (<a href="#CD012493-tbl-0004">Table 3</a>). Reduced gammaglobulin level was also reported to be associated with rituximab treatment (comparing mean level at inclusion 10.8 ± 4.0 g/L versus that at 12 months 8.1 ± 2.2 g/L for rituximab group), although no difference was observed in evaluable participants from either group at 12 months (P = 0.499). </p> <div class="table" id="CD012493-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome ‐ frequency of adverse events (Birgens 2013)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="middle"> <p>Frequency of adverse events (CTCAE grade 1 or above) in study by <a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Rituximab+corticosteroid (%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Corticosteroid only (%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Nausea</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dyspnea</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>16.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dyspepsia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Restless legs</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vertigo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arthralgia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpitation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperglycaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012493-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Primary outcome ‐ frequency of adverse events (Michel 2017)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="middle"> <p>Frequency of severe adverse events in study by <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Rituximab+corticosteroid</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Corticosteroid only</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe adverse events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (3 patients/participants)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (7 patients/participants)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Severe infections (non‐fatal)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> <p>(pneumonia, including one patient with probable pneumocystis infection)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>4</p> <p>(pneumonia = 1; pulmonary abscess =1; diverticulitis = 1; prostatitis = 1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Non‐infectious</p> <p>(non‐fatal)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> <p>(neutropenia)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> <p>(severe pulmonary embolism = 1; spontaneous vertebral fractures = 1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Fatal events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>4</p> <p>(Intracranial tumour = 1; septic shock post‐colonic perforation after colonoscopy = 1; septic and cardiogenic shock post‐amputation for critical limb ischaemia and osteitis; pneumonia = 1) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Gammaglobulin level at 12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>8.1  ±  2.2 g</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>7.7  ±  1.5 g</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012493-sec-0052"> <h4 class="title">Secondary outcome</h4> <p><b>Frequency of partial haematological response (defined as improvement in haemoglobin concentration) at two, six and 12 months</b> </p> <p>Both trials (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) did not report complete response rate at two months (<a href="#CD012493-tbl-0005">Table 4</a>). One study (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>) reported six‐month partial response in figure format, but the corresponding data at 12 months were not reported. The other study (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) did not report response at six months. The evidence is very uncertain about the effect of adding rituximab to glucocorticoids on partial haematological response reported at six months (n = 64; study = 1; RR 0.80, 95% CI 0.24 to 2.71; RR and CI calculated by review authors; GRADE very low certainty) or 12 months (n = 32; study = 1; RR 3.00, 95% CI 0.13 to 68.57; GRADE very low certainty). </p> <div class="table" id="CD012493-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Secondary outcome ‐ partial haematological response</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Number of participants with partial response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Rituximab+corticosteroid</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Corticosteroid only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a> </p> <p>(n = 64 randomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (based on figure from study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (based on figure from study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a> </p> <p>(n = 32 randomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> </tbody> </table> </div> <p><b>RBC transfusion requirement after treatment (measured as units of RBCs transfused per month or millilitres (mL) per kg body weight) at two, six and 12 months</b> </p> <p>Study by Michel and colleagues (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) reported RBC transfusion received by participants up to 12 months, with four participants (mean number of packed red cell units 4.0 ± 2.82) from the rituximab group and five participants from the placebo (corticosteroid only) (mean number of packed red cell units 5.6 ± 4.15) group requiring transfusion, the evidence is very uncertain about the effect of adding rituximab to glucocorticoids (n = 32, RR 0.80, 95% CI 0.26 to 2.45, GRADE very low certainty). Birgens and colleagues (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>) did not report transfusion requirement at the predefined time points, but described no difference in transfusion requirement between the rituximab/corticosteroid and the corticosteroid monotherapy group when comparing responders (CR and PR) from enrolment to end of response or to the end of study follow‐up (34 units versus 30 units, median [range]: 0 [1 to 6] versus 0 [1 to 5], P = 0·81). </p> <p><b>Frequency of DAT positivity after treatment at two, six and 12 months</b> </p> <p>Study by Michel and colleagues (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) reported positive DAT at 12 months in 5/13 (38%) participants who received rituximab and corticosteroid and compared to 8/10 (80%) participants who received placebo (corticosteroid only). DAT positivity was not reported by study by Birgensand colleagues (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>). </p> <p><b>Overall survival at six and 12 months</b> </p> <p>Overall survival at these specific time points was not reported by either study. Michel and colleagues (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>) reported the death of six participants treated with corticosteroid only versus none with combination of rituximab and corticosteroid at two years (P = 0.017). </p> <p><b>Relapse‐free survival (RFS) at six and 12 months</b> </p> <p>RFS rates at six and 12 months was not explicitly reported by either study. In the study byBirgens and colleagues <a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>), RFS in all responders was higher in the participants receiving rituximab and prednisolone combined (P = 0·02) corresponding to a hazard ratio (HR) of 0·33 (95% Cl 0·12 to 0·88; RR and CI calculated by review authors). In the study by Michel and colleagues (<a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>), RFS was better for the rituximab group (P = 0.023). </p> <p><b>Frequency of relapse at six and 12 months</b> </p> <p>Frequency of relapse at six an 12 months was not reported in either study. <a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a> reported that at 36 months, about 70% of the participants who showed either CR or PR were still relapse‐free in the combination treatment group, versus about 45% in the prednisolone monotherapy group (P = 0.02). </p> <p><b>Quality of life (QOL) as measured by validated instruments at 12 months</b> </p> <p>QOL measures were not reported by either included study.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012493-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012493-sec-0053"></div> <section id="CD012493-sec-0054"> <h3 class="title" id="CD012493-sec-0054">Summary of main results</h3> <p>In this review, two randomised controlled trials (RCTs) with 96 participants suffering from primary warm‐antibody autoimmune haemolytic anaemia (AIHA) were included (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>, <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>). These studies compared the efficacy of treatment with rituximab combined with corticosteroid versus with corticosteroid alone in adults. No RCTs studying other interventions for AIHA were found. </p> <p>The addition of rituximab to corticosteroid resulted in higher complete haematological response rates at 12 months (two trials). Relapse‐free survival (RFS) was better in the rituximab group with follow‐up up to four and eight years, respectively in two trials. The proportion of participants with partial haematological response reported at six months (one trial) and 12 months (one trial) did not differ with the addition of rituximab to corticosteroid. REd blood cell (RBC) transfusion requirement was also similar between the two study arms (two trials). Lower rate of direct antiglobulin test (DAT) positivity at 12 months was reported in the rituximab arm (one trial). Similar frequencies of adverse effects and serious adverse events were observed between the two groups (one trial). </p> </section> <section id="CD012493-sec-0055"> <h3 class="title" id="CD012493-sec-0055">Overall completeness and applicability of evidence</h3> <p>While the included studies offered evidence for the efficacy of adding rituximab to corticosteroid in adults with warm‐type AIHA for induction of complete or partial haematological response, the reported data did not allow some other predefined primary and secondary objectives to be addressed. In particular, there is a lack of data on patient‐relevant outcome including adverse effects, overall survival (OS,) RFS and quality of life (QOL) of participants involved. This patient‐centered information would be crucial in the decision‐making process for people with AIHA considering the use of rituximab, beyond rate of recovery in haematological parameters. On the other hand, RCTs are only available on comparing the use of rituximab in combination with corticosteroid against corticosteroid alone, this did not provide evidence for the use of other immunomodulatory therapies such as corticosteroid alone, splenectomy, mycophenolate mofetil (MMF), or intravenous immunoglobulin (IVIg). This represents a major limitation of our review and offers no support for physicians to consider alternative agents or in people who fail with rituximab and steroid therapy. Such observation also implies that most immunomodulatory agents have been used based non‐randomised trials and as off‐label indications. AIHA also refers to a broad spectrum of entities. The included RCTs only recruited adults and those with newly diagnosed, warm‐type AIHA, limiting generalisability especially for people with relapsed disease, and those with cold‐type AIHA where the pathogenic mechanism differs The disease in the paediatric age group and as well as effective strategies for cold‐type or relapsing AIHA remain to be evaluated in high‐quality clinical trials. The lack of data on QOL measures should be noted as AIHA is a chronic condition. Overall, high‐quality evidence on the management of AIHA is still lacking. </p> </section> <section id="CD012493-sec-0056"> <h3 class="title" id="CD012493-sec-0056">Quality of the evidence</h3> <p>One of the two included studies had low risk of bias, the other study had high risk of performance and detection bias due to lack of blinding. The overall certainty quality of evidence for complete haematological response was low, as one of the included trials had high risk of bias and the overall sample size was small. The overall certainty of evidence for partial haematological response and RBC transfusion requirement were very low, as both outcomes were based on only one trial and sample size was small. This calls for the need for further blinded RCTs to consolidate the available data on the benefit of combining rituximab with corticosteroid over corticosteroid monotherapy. </p> </section> <section id="CD012493-sec-0057"> <h3 class="title" id="CD012493-sec-0057">Potential biases in the review process</h3> <p>We performed a independent,extensive literature search by two review authors for published RCTs. It is possible that studies may be missed by our current strategy. The limited number of studies included did not allow us to analyse for publication bias using a funnel plot. </p> </section> <section id="CD012493-sec-0058"> <h3 class="title" id="CD012493-sec-0058">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are in line with a meta‐analysis of 21 studies (<a href="./references#CD012493-bbs2-0032" title="ReynaudQ , DurieuI , DutertreM , LedochowskiS , DuruptS , MichalletAS , et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmunity Reviews2015;14(4):304-13. ">Reynaud 2015</a>), of which 20 were non‐randomised observational studies and one being an RCT included in our review (<a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a>), which suggested efficacy and safety in the use of rituximab for AIHA. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012493-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/urn:x-wiley:14651858:media:CD012493:CD012493-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012493-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_t/tCD012493-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012493-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/urn:x-wiley:14651858:media:CD012493:CD012493-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012493-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_t/tCD012493-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012493-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/urn:x-wiley:14651858:media:CD012493:CD012493-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Rituximab with steroid versus steroid, outcome: 1.1 Complete haematological response at 12 months." data-id="CD012493-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_t/tCD012493-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Rituximab with steroid versus steroid, outcome: 1.1 Complete haematological response at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012493-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/urn:x-wiley:14651858:media:CD012493:CD012493-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rituximab with steroid versus steroid, Outcome 1: Complete response at 12 months" data-id="CD012493-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_t/tCD012493-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Rituximab with steroid versus steroid, Outcome 1: Complete response at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/references#CD012493-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/media/CDSR/CD012493/image_n/nCD012493-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012493-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rituximab plus corticosteroid compared with corticosteroid (+/‐ placebo) for warm AIHA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with newly diagnosed warm AIHA </p> <p><b>Settings:</b> referral centres </p> <p><b>Intervention:</b> rituximab plus corticosteroid </p> <p><b>Comparison:</b> corticosteroid only </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corticosteroid only</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rituximab and corticosteroid only</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complete haematological response at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>313 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.13</b> (1.34 to 3.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>low<b>#</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Frequency of adverse events at two, six and 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The included studies did not report frequency of adverse events at two, six an 12 months </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Partial haematological response at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.00</b> (0.13 to 68.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>very low<b>$</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only reported by <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall survival at six and 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The included studies did not report OS</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse‐free survival at six and 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The included studies did not report RFS at specific time points</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RBC transfusion requirement after treatment at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>313 per 1000</b> (mean number of packed red cell units 5.6 ± 4.15) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>250 per 1000</b> (mean number of packed red cell units 4.0 ± 2.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.80</b> (0.26 to 2.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only reported by <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a>. The included studies did not report transfusion requirement at two and six months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QOL as measured by validated instruments at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The included studies did not report QOL measures</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>OS:</b> overall survival; <b>QoL:</b> quality of life; <b>RBC:</b> red blood cell; <b>RCT:</b> randomised controlled trial; ; <b>RFS:</b> relapse‐free survival<b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>#Evidence from RCT downgraded because of high risk of bias in study design and small sample size. </p> <p>$Evidence from RCT downgraded because of imprecision in results and small sample size.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012493-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Primary outcome ‐ complete haematological response</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Number of participants with complete response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Rituximab+corticosteroid</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Corticosteroid only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a> </p> <p>(n = 64 randomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a> </p> <p>(n = 32 randomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Primary outcome ‐ complete haematological response</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012493-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome ‐ frequency of adverse events (Birgens 2013)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="middle"> <p>Frequency of adverse events (CTCAE grade 1 or above) in study by <a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Rituximab+corticosteroid (%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Corticosteroid only (%)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Nausea</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dyspnea</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>16.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Dyspepsia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Restless legs</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vertigo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arthralgia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpitation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperglycaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Primary outcome ‐ frequency of adverse events (Birgens 2013)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012493-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Primary outcome ‐ frequency of adverse events (Michel 2017)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="middle"> <p>Frequency of severe adverse events in study by <a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Rituximab+corticosteroid</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Corticosteroid only</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe adverse events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (3 patients/participants)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (7 patients/participants)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Severe infections (non‐fatal)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> <p>(pneumonia, including one patient with probable pneumocystis infection)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>4</p> <p>(pneumonia = 1; pulmonary abscess =1; diverticulitis = 1; prostatitis = 1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Non‐infectious</p> <p>(non‐fatal)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> <p>(neutropenia)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>2</p> <p>(severe pulmonary embolism = 1; spontaneous vertebral fractures = 1)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Fatal events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>4</p> <p>(Intracranial tumour = 1; septic shock post‐colonic perforation after colonoscopy = 1; septic and cardiogenic shock post‐amputation for critical limb ischaemia and osteitis; pneumonia = 1) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>Gammaglobulin level at 12 months</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>8.1  ±  2.2 g</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"> <p>7.7  ±  1.5 g</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Primary outcome ‐ frequency of adverse events (Michel 2017)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012493-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Secondary outcome ‐ partial haematological response</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>Number of participants with partial response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Rituximab+corticosteroid</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Corticosteroid only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012493-bbs2-0001" title="BirgensH , FrederiksenH , HasselbalchHC , RasmussenIH , NielsenOJ , KjeldsenL , et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. British Journal of Haematology2013;163(3):393-9. ">Birgens 2013</a> </p> <p>(n = 64 randomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (based on figure from study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (based on figure from study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012493-bbs2-0002" title="MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , GuennoGL , et al. A multi-centre randomized and double-blind controlled trial of rituximab for warm autoimune hemolytic anemia in adults. In: Blood. Vol. 126. 2015:3338. MichelM , TerriouL , Roudot-ThoravalF , HamidouM , EbboM , Le GuennoG , et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology2017;92(1):23-7. ">Michel 2017</a> </p> <p>(n = 32 randomised)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Secondary outcome ‐ partial haematological response</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/full#CD012493-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012493-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rituximab with steroid versus steroid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Complete response at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.34, 3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rituximab with steroid versus steroid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012493.pub2/references#CD012493-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012493.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012493-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012493-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012493-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012493-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012493-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012493-note-0010">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012493-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012493-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012493-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012493\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012493\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012493\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012493\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012493\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012493.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012493.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012493.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012493.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012493.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729311660"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012493.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729311664"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012493.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed9cd6a26f4a4',t:'MTc0MDcyOTMxMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 